Publications by authors named "Peter Amlot"

Claim this Profile
A
A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.
Gairin Dancey, John Violet, Alessandra Malaroda, Alan J Green, Surinder K Sharma, Peter Amlot

Clin Cancer Res· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial of epstein-barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation.
Lesley Rees, E Jane Tizard, Andrew J Morgan, W David Cubitt, Susan Finerty, Peter L Amlot

Transplantation· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapamycin-induced remission of Kaposi's sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets.
Stephen B Walsh, Shaun A Summers, Peter L Amlot, Michael T Sheaff, Guy H Neild

NDT Plus· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A quantitative assay for Epstein-Barr Virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease.
Amy E Guppy, Eira Rawlings, J Alejandro Madrigal, Peter L Amlot, Linda D Barber

Transplantation· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
Tanzina Haque, Gwen M Wilkie, Marie M Jones, Craig D Higgins, Gillian Urquhart, Peter L Amlot

Blood· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases.
Gwen M Wilkie, Clare Taylor, Marie M Jones, David M Burns, Marc Turner, Peter L Amlot

J Immunother· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type-1 histiocytosis response to 90Y-lanreotide.
Nicholas Turner, Peter Amlot, Andrew Platts, Alison Jones, John Buscombe

Lancet Oncol· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
B-cell lymphoma arising around a PTFE graft.
Sally M A Hamour, Patrick F K Yong, Peter Amlot, Aine Burns

Nephrol Dial Transplant· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia.
Veronique M Duke, Domenica Gandini, Paul D Sherrington, Ke Lin, Bridget Heelan, Peter Amlot

Haematologica· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.
Bridget T Heelan, Vincent Tormey, Peter Amlot, Elspeth Payne, Atul Mehta

Br J Haematol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells.
Tanzina Haque, Gwen M Wilkie, Clare Taylor, Peter L Amlot, Parvez Murad

Lancet· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis